{"id":3562,"date":"2025-06-02T08:54:11","date_gmt":"2025-06-02T06:54:11","guid":{"rendered":"https:\/\/remeds.org\/?p=3562"},"modified":"2025-11-14T09:26:07","modified_gmt":"2025-11-14T08:26:07","slug":"umass-licenses-sirna-mecp2-duplication-syndrome","status":"publish","type":"post","link":"https:\/\/remeds.org\/hr\/2025\/06\/02\/umass-licenses-sirna-mecp2-duplication-syndrome\/","title":{"rendered":"Novi korak naprijed u potrazi za lijekom: UMass Chan licencira siRNA tehnologiju \u00a0"},"content":{"rendered":"<p>Medicinski fakultet UMass Chan licencirao je obe\u0107avaju\u0107u tehnologiju utemeljenu na siRNA tvrtki M2DS, novonastaloj tvrtki posve\u0107enoj unapre\u0111enju te tehnologije kao lijeka za Sindrom duplikacije MECP2. Ovo predstavlja zna\u010dajan korak naprijed u pretvaranju najsuvremenijih istra\u017eivanja u klini\u010dku zbilju.<a href=\"https:\/\/dupmecp2.eu\/recruitement-hero\/\"><\/a><\/p>\n\n\n\n<p>Tehnologija je razvijena u laboratoriju dr. Khvorove, a projekt je vodio Vignesh Hariharan. Rana istra\u017eivanja provedena su zahvaljuju\u0107i financiranju od Cure MDS i Rett Syndrome Research Trust. Ovaj siRNA djeluje ciljanjem i razgradnjom glasni\u010dke RNK odgovorne za prekomjernu proizvodnju MeCP2 proteina. <\/p>\n\n\n\n<p>U studijama na mi\u0161evima, doza je u\u010dinkovito dospjela do mozga i le\u0111ne mo\u017edine te bi mogla zahtijevati samo jedan ili dvaput godi\u0161nje doziranje. Licenciranjem ove tehnologije M2DS-u, terapija sada ulazi u fazu u kojoj mo\u017ee dobiti podr\u0161ku potrebnu za napredak prema ispitivanjima na ljudima. <\/p>\n\n\n\n<p>Osim teku\u0107ih klini\u010dkih ispitivanja tvrtki Ionis i HuidaGene, ova prekretnica mo\u017ee dodati obe\u0107avaju\u0107i dodatak nizu potencijalnih terapija za ovaj rijedak i slo\u017een poreme\u0107aj.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><a href=\"https:\/\/bridge.umassmed.edu\/s\/news\/news-article\/umass-chan-licenses-sirna-therapeutics-for-mecp2-duplication-syndrome-MCMWKNCJYQ25CQHF5YITTOM757HU\">Pogledajte priop\u0107enje za javnost<\/a><\/p>\n\n\n\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>UMass Chan Medical School has licensed a promising siRNA-based technology to M2DS, a startup company dedicated to advancing the technology as a treatment for MECP2 Duplication Syndrome. This marks a major step forward in translating cutting-edge research into clinical reality. The technology was developed in the lab of Dr. Khvorova, with the project led by [&hellip;]<\/p>\n","protected":false},"author":114,"featured_media":3563,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jf_save_progress":"","footnotes":""},"categories":[9,24],"tags":[],"class_list":["post-3562","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research","category-sirna"],"_links":{"self":[{"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/posts\/3562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/users\/114"}],"replies":[{"embeddable":true,"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/comments?post=3562"}],"version-history":[{"count":3,"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/posts\/3562\/revisions"}],"predecessor-version":[{"id":3567,"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/posts\/3562\/revisions\/3567"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/media\/3563"}],"wp:attachment":[{"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/media?parent=3562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/categories?post=3562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/tags?post=3562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}